Table 1. Summary of prospective clinical trials testing BRAF +/− MEK inhibitor therapies for metastatic NSCLC with Class 1 BRAF mutations.
| Study | Therapeutic agents | No. of patients | Overall response rate | PFS, months [median (95% CI)] |
OS, months [median (95% CI)] |
Grade 3 or greater adverse events |
|---|---|---|---|---|---|---|
| Subbiah et al. JCO Precis Oncol, 2019 (15) | Vemurafenib | 62 | 81% | |||
| Previously treated | 54 | 37% | 6.1 (5.1–8.3) | 15.4 (8.2–22.6) | ||
| Naïve | 8 | 37.5% | 12.9 (4.0–NE) | NE (4.0–NE) | ||
| Mazieres et al. Ann Oncol, 2020, (16) | Vemurafenib | 101 | 45% | 5.2 (3.8–6.8) | 10.0 (6.8–15.7) | Serious adverse events—36% |
| Previously treated | 80 | |||||
| Naïve | 21 | |||||
| Planchard et al. Lancet Oncol, 2016, (17) | Dabrafenib | 84 | 45% | |||
| Previously treated | 78 | 33% | 5.5 (2.8–7.3) | 15.4 (7.3–NE) | ||
| Naïve | 6 | 67% | 8.4 | |||
| Planchard et al. Lancet Oncol, 2016, (20) | Dabrafenib + trametinib | 57 | 68% | 10.2 (6.9–16.7) | Not described | 75% |
| Previously treated | 57 | |||||
| Naïve | 0 | |||||
| Planchard et al. Lancet Oncol, 2017, (19) | Dabrafenib + trametinib | 36 | 64% | 10.9 (7.0–16.6) | 24.6 (12.3–NE) | 73% |
| Previously treated | 0 | |||||
| Naïve | 36 | |||||
| Salama et al. J Clin Oncol, 2020, (18) | Dabrafenib + trametinib | 5 | 25% | 6.6 | Not described | N/A |
| Previously treated | ||||||
| Naïve | ||||||
| Riely et al. J Clin Oncol, 2023, (2) | Encorafenib + binimetinib | 98 | NE | 42% | ||
| Previously treated | 39 | 46% | 9.3 (6.2–NE) | |||
| Naïve | 59 | 75% | NE (15.7–NE) |
NSCLC, non-small cell lung cancer; PFS, progression-free survival; CI, confidence interval; OS, overall survival; NE, not evaluable.